HIV血清質控盤（Qualification Panels）

廣州健侖生物科技有限公司

SeraCare Life Sciences公司主要在美國、歐洲和亞洲提供促進人類和動物診斷和治療學的探索、開發(fā)和生產的產品和服務。其業(yè)務分為兩個部分：診斷和生物制藥產品和生物服務。診斷和生物制藥產品部門生產和銷售診斷和控制面板產品，用于測試傳染性疾病的臨床實驗室及員工培訓和能力測試。生物服務部門提供生物銀行、來樣加工和測試服務。

美國SeraCare收購BBI公司，即原BBI血清盤已經改名為SeraCare血清盤。

其產品包括有：傳染病陽性質控品、疾病標準品、細菌陽性質控品、人血清白蛋白、人伽馬球蛋白、牛血清白蛋白、血清盤、人血漿、人血清。

SeraCare的血清盤包括：HIV-1轉化盤、HIV性能盤、HBV轉化盤、HBV性能盤、HCV轉化盤、HCV性能盤、弓形蟲性能盤、線性盤和質控盤等等。

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

美國Seracare HIV血清質控盤（Qualification Panels）

美國Seracare

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【市 場 部】    楊永漢

【】 

【騰訊Q Q】 2042552662

【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

線粒體是人類細胞將糖轉化成能量的重要工廠。西奈山伊坎醫(yī)學院的科學家們開發(fā)了一種新測序技術，可以幫助人們理解線粒體基因對個體患病風險的影響，比如糖尿病、心臟病和癌癥。這項研究發(fā)表在近期的Nucleic Acids Research雜志上。
在年齡、體重和壞習慣(比如吸煙)相同的人中，有些會生病有些卻不會。研究者們一直對這一點感到迷惑，并嘗試通過飲食和核基因來確定個體的患病風險。但這樣的分析遺漏了線粒體基因(mtDNA)的差異，mtDNA遺傳自我們的母親，每個細胞都有這樣的DNA。
近年來研究表明，線粒體發(fā)生錯誤會引起嚴重的疾病。然而由于mtDNA的異質性很大，分析mtDNA變異對個體疾病風險的影響非常復雜。
這項研究展示了*可以準確鑒定mtDNA異質性的測序技術，Mseek。細胞里的mtDNA含量很少，過去這方面一直沒有什么進展。人們意識到了mtDNA的異質性，但卻無法再單細胞水平上建立決定性的理論。
“研究者們一直在尋找能夠準確測序mtDNA的低成本方法，”西奈山伊坎醫(yī)學院的助理教授Ravi Sachidanandam博士說。“現(xiàn)在我們做到了這一點。Mseek可以鑒定線粒體中的功能紊亂，使mtDNA成為了有用的生物學指標。此外，人們還可以將mtDNA作為潛在的靶標，治療癌癥和多種遺傳疾病。”
據Dr. Sachidanandam介紹，新測序技術達到了*的靈敏性、特異性和測序深度，能夠得到高純度的mtDNA，檢測不同版本的mtDNA或mtDNA變體。
Mseek主要是利用酶清除細胞核DNA，只留下線粒體DNA進行測序。研究人員將Mseek用于多個細胞系，鑒定了不同細胞樣本中的mtDNA“指紋”。他們還通過追蹤mtDNA變體發(fā)現(xiàn)，mtDNA異質性在單細胞水平上是穩(wěn)定維持的。

Mitochondria are important plants where human cells convert sugar into energy. Scientists at the Icahn School of Medicine in Mount Sinai have developed a new sequencing technology that can help people understand the impact of mitochondrial genes on individual risk factors such as diabetes, heart disease and cancer. This study was published in the recent issue of Nucleic Acids Research.
Some people who are the same in age, weight, and bad habits (such as smoking) are sick but not others. Researchers have always been puzzled by this and tried to determine the risk of the individual through diet and nuclear genes. But such an analysis missed the difference in mitochondrial genes (mtDNA) that we inherited from our mother, and each cell has such DNA.
Recent studies have shown that mistakes in mitochondria can cause serious diseases. However, due to the heterogeneity of mtDNA, it is very complicated to analyze the impact of mtDNA mutation on individual disease risk.
This study shows the first sequencing technology that can accuray identify mtDNA heterogeneity, Mseek. The mtDNA content in the cells is very small, and there has been little progress in this area. People are aware of the heterogeneity of mtDNA but can no longer establish deterministic theories at the single cell level.
“Investigators are always looking for low-cost methods that can accuray sequence mtDNA,” said Dr. Ravi Sachidanandam, an assistant professor at Icahn Medical School in Mount Sinai. "Now we have done this. Mseek can identify functional disorders in mitochondria, making mtDNA a useful biological indicator. In addition, people can use mtDNA as a potential target for the treatment of cancer and many genetic diseases."
According to Dr. Sachidanandam, the new sequencing technology has achieved unprecedented sensitivity, specificity, and sequencing depth, enabling high-purity mtDNA to detect different versions of mtDNA or mtDNA variants.
Mseek uses enzymes to remove nuclear DNA, leaving only mitochondrial DNA for sequencing. The researchers used Mseek for multiple cell lines and identified mtDNA "fingerprints" in different cell samples. They also found that by tracking mtDNA variants, mtDNA heterogeneity was stable at the single cell level.